Hi [[ session.user.profile.firstName ]]
Sort by:
    • Practical Application of a Rapid Microbiological Method (RMM) in Pharmaceutical Practical Application of a Rapid Microbiological Method (RMM) in Pharmaceutical Scott Sutton Ph.D. and Yongqiang Zhang Recorded: Dec 16 2014 3:00 pm UTC 59 mins
    • The application of Rapid Microbiological Methods (RMM) in a topic that has gained interest over the past few years as pharmaceutical manufacturers investigate and look to gain improved efficiencies across all areas of their businesses – including the microbiology laboratory. This presentation will show how a rapid method can provide a solution to a common microbiological testing problem for pharmaceutical manufacturers – process water microbiology testing.

      *** Presented by Yongqiang Zhang, Senior Scientist, BD Diagnostics:

      Examination of the microbiological quality of water used for manufacturing pharmaceuticals is integral to current Good Manufacturing Practices (GMP) and ensuring product safety. Membrane filtration, the conventional method for assessing microbial burden in water, takes three to seven days to complete. Valuable opportunities for intervention could be missed due to a delay in obtaining test results. In this study, we assessed the effectiveness of flow cytometry as a rapid microbiology method for water analysis. The data with four representative bacteria [Burkholderia cepacia, Escherichia coli, Pseudomonas aeruginosa and Staphylococcus aureus] indicate that a low level bacterial presence in water can be rapidly detected and enumerated. These results highlight the potential of flow cytometry for real time monitoring of the microbiological quality of water in pharmaceutical manufacturing.

      *** Presented by Scott Sutton Ph.D. – President of Pharmaceutical Microbiology Forum & Owner of The Microbiology Network

      There has been excitement about the potential of RMM in QC microbiology since the ATP bioluminescence method was commercialised in the early 1970s. After 45 years however, pharma microbiology is notable for its lack of adoption of these methods. This presentation will examine this situation and offer some potential explanations, as well as recommendations for better microbiology service to the pharmaceutical industry.

      Read more >
    • Pharmaceutical Manufacturing Regulations: Navigating the Complexities Pharmaceutical Manufacturing Regulations: Navigating the Complexities Michael A. Dotlich (Eli Lilly and Company) / Bei Ma (USP) / Dr. Claire Dentinger (Rigaku Raman Technologies) Recorded: Jan 30 2014 3:00 pm UTC 67 mins
    • During this webinar learn more about unconventional approaches to enhance quality programs with the use of modern handheld technology...

      While regulatory enforcement agencies around the world have increased scrutiny on quality assurance/quality control programs, pharmaceutical manufacturers are increasingly looking for ways to lean out the manufacturing process without compromise to product quality. This push and pull conundrum has manufacturers seeking guidance on global industry regulations while searching for alternatives to legacy quality practices. With the expanding supply chain and the onset of globalization, it is now more important than ever to adjust quality programs to improve efficiency but remain keen on effectiveness for the continued promise of product quality and patient safety.

      Handheld Raman technology is currently being implemented by global pharmaceutical manufacturers and regulatory agencies around the world providing an effective alternative approach to increased testing and heightened quality programs.

      Read more >
    • Overcome Hurdles to Effective Pharmaceutical Marketing Overcome Hurdles to Effective Pharmaceutical Marketing By PharmaGuy, aka John Mack Author, Pundit, Blogger, Editor of Pharma Marketing News Upcoming: Feb 18 2016 3:00 pm UTC 45 mins
    • Topics and discussion points include:

       Regulations: What are the most often cited violations? Are pharma marketers getting better at compliance? Cautionary tales – beware of agencies with limited regulatory experience.

       Ethics: Why are ethics in marketing important? What ethical principles should pharmaceutical marketers obey, especially in the digital realm? A bit of history: The eHealth Code of Ethics

       Transparency: Do you have a transparency policy? Is transparency good in theory, but not in practice?

       Patient Power: How are patients affecting pharmaceutical marketing? Mining the views of patients via social media to guide you marketing efforts.

       Digital: How digital media and mobile are disrupting pharma marketing and what to do about it. What digital marketing channels are preferred by physicians?

      Read more >
    • Pharmaceuticals Market Briefing Pharmaceuticals Market Briefing Rathanesh Ramasundram Recorded: Jun 26 2015 1:30 am UTC 62 mins
    • The Asia Pacific is the third largest pharmaceutical market in the world after North America and Europe, with generics being the major driver for the pharmaceutical industry in this region, aided by factors such as the aging population and impending expiry of patented drugs. It is a necessity for pharmaceutical companies to be aware of the key trends in the APAC generics market and maximise the market opportunities in order to remain relevant.

      In today’s rapidly evolving business landscape, pharmaceutical companies are also starting to realise the importance of the customer experience as a key differentiator. With a gradual shift from product to the customer, the pharmaceutical industry needs to keep up with other industries in terms of providing the perfect digital customer experience. A well-executed digital strategy is essential for today’s pharmaceutical companies to better connect with their clients.

      Join us as we discuss these and other key topics.

      Read more >
    • Making continuous processing a reality in the pharmaceutical industry Making continuous processing a reality in the pharmaceutical industry Mark Gibson and Marcel de Matas Recorded: Aug 21 2013 2:35 pm UTC 31 mins
    • The principal benefits of continuous processing are considered to be reduced cost, increased speed, agility and quality. Use of such technology for pharmaceutical products is in its relative infancy despite the existence of appropriate processing platforms. Notable perceived barriers to the use of continuous manufacturing are with the initial capital spend, regulatory uncertainties and low technical competence limiting its uptake. This presentation provides details of early experiences with continuous drug product manufacture in the pharmaceutical industry and identifies areas of focus which is believed will drive adoption of this technology for the benefit of future pharmaceutical production.

      Read more >
    • Accelerating Pharma R&D using Mass Spectrometry and NMR Accelerating Pharma R&D using Mass Spectrometry and NMR University of Dundee & Bruker Daltonics Recorded: May 26 2015 2:00 pm UTC 54 mins
    • Accelerating Pharma R&D with Novel MS Applications for High Throughput Screening (HTS), Drug Imaging and Integrating MS and NMR data for high confidence structure verification of small molecules.

      This webinar will introduce novel MS and NMR solutions and its applications in pharmaceutical research:

      > NMR Spectroscopy and Mass Spectrometry are two fundamental techniques for small molecule structure verification. Bruker FUSION-SV - a new software solution for comprehensive fully automated small molecule structure verification – simplifies and accelerates the drug design and discovery phases in the pharmaceutical industry significantly. The new Bruker FUSION-SV™ is a software solution integrating high resolution accurate mass (HRAM) data and complementary NMR data, into one result - increasing significantly the specificity and throughput for small organic molecule structure verification. Synthesis chemists will get a prompt result without being an expert spectroscopist.

      > Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) instruments are ideally suited for high throughput screening (HTS) in drug discovery. Not only speed, simplicity and robustness are the convincing arguments for MALDI-TOF MS but the inherent strength of a label- and solvent-free technique. The webinar will explain the technique and advantages of MALDI-TOF MS and present automation solutions for highest throughput and speed (less than 1 second per sample).

      > Finally the webinar will describe how the MALDI technology is used for small molecule imaging when coupled to modern 7 T (Tesla) FT-MS instrumentation. Drugs and metabolites can be visualized and distinguished one from the other directly measured from tissue samples. These results can be linked with histological information derived from the very same tissue, giving new insights into drug action and toxicity.

      Read more >
    • Sales reps in the digital age Sales reps in the digital age Dominic Tyer Recorded: Jul 9 2015 12:00 pm UTC 76 mins
    • As the number of doctors willing to see pharmaceutical sales representatives in person declines how can digital tools help with access, reach and rep effectiveness?

      One of the factors blamed for the reduction in access was digital preferences – particularly among younger doctors.

      However, digital interactions – though clearly on the rise – can will never entirely supersede face-to-face contact, so how can the industry best get the digital/face-to-face mix right?

      This PMGroup webinar, in association with M3 Europe and Veeva Systems, will look at the place of sales reps in the digital age and how best to support them with digital tools and channels.

      Read more >
    • Next-generation KOL Intelligence: Better insight, better outcomes Next-generation KOL Intelligence: Better insight, better outcomes Dominic Tyer Recorded: May 13 2015 1:00 pm UTC 61 mins
    • Advances in KOL Intelligence are delivering richer insights into clinical landscapes than ever before. The pharmaceutical organisations which harness these insights to inform strategic planning will be better able to meet the challenges of an increasingly competitive and complex environment for KOL Engagement. There’s a wealth of information out there, but it’s not all about Big Data – it’s about smart data and insight that you can easily act on.
      Is your KOL Intelligence a mass of data, or is it a tool that broadens your understanding of influence and helps you make smarter decisions? Can you confidently identify who’s suitable for ad boards? Are your network maps simply impressive graphics, or a tool for better engagement? Or are you new to KOL intelligence and looking for guidance on where to begin?
      As the pioneers of KOL mapping and the UK's leading KOL intelligence agency, we believe the strength of our work doesn't simply lie in the quality of our research, but in how we help our clients understand it. If you’re new to KOL intelligence we’d like to show you what you can learn. And if you already know how valuable it is, you’ll understand how important it is to stay on top of the latest trends in KOL analysis.
      On May 13th, at 12pm (GMT), in association with PMLiVE, Kendle Healthcare will host a free webinar, “Next-generation KOL Intelligence: Better insight, better outcomes”, which will help you understand how to use KOL intelligence to make better-informed decisions. Our webinar will be interactive and we welcome any questions you may have.

      Read more >
    • A Practical 2D-LC System Developed for Complex Pharmaceuticals A Practical 2D-LC System Developed for Complex Pharmaceuticals Lianjia Ma, Ph.D.* and Anthony Alexander, Ph.D. Recorded: Mar 23 2011 3:00 pm UTC 31 mins
    • A comprehensive two-dimensional liquid chromatograph (LC × LC) was constructed from commercially available conventional HPLC equipments. This system utilizes two independently configurable 2nd dimension binary pumping systems to deliver independent flow rates, gradient profiles and mobile phase compositions to dual Fused-Core secondary columns. Very fast gradient separations (30 seconds total cycle time) were achieved at ambient temperature without excessive backpressure and without compromising optimal 1st dimension sampling rates by using superficially porous stationary phases. A practical approach to optimize the various inter-related instrumental parameters will also be presented.

      Read more >
    • Designing unique patient solutions in rare disease Designing unique patient solutions in rare disease Clare Bates Recorded: Jul 15 2014 1:00 pm UTC 51 mins
    • Living with any chronic health condition can be demanding, but rare diseases bring a unique set of challenges for patients.

      These can range from diagnosis difficulties to limited information and support, a lack of knowledge - even within medical services - and social stigma. Such challenges negatively impact patients and carers - preventing the best possible health outcomes from being achieved.

      This webinar will help pharmaceutical companies understand how they can better address the unmet needs of such patients.

      On Tuesday 15 July at 2pm this free event will feature a health psychology specialist and a patient research expert, who will discuss how a ‘belief-based’ support approach can be delivered.

      The webinar will also investigate how a long-term strategy that accommodates the changing support needs of individual patients from childhood to adulthood can be delivered at a global level – while still resonating at an individual level for patients.

      Read more >
    • Biased ligands in Drug Discovery: the case of TRV027 Biased ligands in Drug Discovery: the case of TRV027 Nicolas Pierre (Cisbio Bioassays) & William Gowen-MacDonald (Trevena) Recorded: Jun 30 2015 2:00 pm UTC 27 mins
    • [UPDATE]

      Special Guest Terry Kenakin Ph.D. will be taking part in our LIVE Q&A session answering your questions!


      Ligand bias is a well-established concept in the GPCR research field that is beginning to emerge as a means to optimize GPCR targeted drug design. Most approved medications that target GPCRs act as either agonists or antagonists of heterotrimeric G protein and β-arrestin pathways. In many cases, this classical signaling paradigm leads to both efficacy and on-target adverse events. Biased GPCR ligands have the ability to activate or inhibit with greater selectivity one of the two downstream effector proteins and its subsequent signaling cascades. The goal of this webinar is to illustrate in vitro characterization of GPCR ligand bias and its translation to in vivo proof-of concept using TRV027, an AT1R modulator, as an exemplar biased ligand.

      > What attendees will learn about?

      • Review of GPCR signaling
      • Introduction to concept of ligand bias and quantification thereof
      • Utility of 2nd messenger assays in GPCR drug discovery
      • Pre-clinical biased ligand proof-of-concept

      Read more >